Replies to post #69498 on Biotech Values

[mcbio]

Biotech rule of thumb: If it's a piece of information that bodes well for the trial, then 90% of small biotechs will make sure it is stated clearly and advantageously in the PR.

Conversely, if there are ambiguities, they are there because the specifics themselves may add a negative hue to the results.

I can't argue with that. To be truly clear, they would have stated a p value and would have made it very clear whether or not all events had occurred in the control arm. I'm not sure if the fact that they seem to imply that is enough for me to pull the trigger on this one. I may just wait for more data.

[microcapfun]

>>Biotech rule of thumb: If it's a piece of information that bodes well for the trial, then 90% of small biotechs will make sure it is stated clearly and advantageously in the PR.

Conversely, if there are ambiguities, they are there because the specifics themselves may add a negative hue to the results.<<

Consider your post 'recommended', pgs!

micro